Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Completed · Phase 1

Conditions studied: Alzheimer Disease, Parkinson Disease, Healthy Volunteers

In brief

The primary objective of this protocol is to examine \[18F\]MNI-1126 as a tool to assess synaptic density loss.

Key facts

Study ID

NCT03587649

Run by

Invicro

People needed

12

Starts

2018-05-07

Expected to finish

2020-02-26

Last updated by the study team

2020-04-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Invicro — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.